RxDoctor Payments Data

Bridget Young

Family · Vassar, MINPI 1003228040

Payments from drug & device makers

$1,904in general payments, 2019–2025

Across 43 payments — averaging $44.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$515
  • Novo Nordisk$364
  • Johnson & Johnson$311
  • GSK$143
  • AbbVie$117
  • Lilly USA, LLC$105
  • plus $350 from 6 others

What the payments were for

  • Food & beverage$1,904100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,904 in reported general payments places this provider in the 80th percentile of 3,657 family providers in Michigan.

See all family providers in Michigan

Medicare billing

Part B allowed, 2024
$12,333
Medicare patients
79
Services billed
1,977

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide70$124,825
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$40,981
JardianceEmpagliflozin34$40,042
EliquisApixaban27$36,455
TrulicityDulaglutide19$34,821
VraylarCariprazine Hcl20$27,185
XareltoRivaroxaban21$18,020
VeozahFezolinetant12$6,642
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$4,117
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen118$2,884
Omeprazole144$2,491
Atorvastatin Calcium180$2,479
Potassium Chloride50$1,697
Albuterol Sulfate HfaAlbuterol Sulfate57$1,660
Gabapentin122$1,316

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$364$124,82570 claims
GSKTrelegy Ellipta$143$40,98133 claims
Lilly USA, LLCTrulicity$105$34,82119 claims
AbbVieVraylar$117$27,18520 claims
Johnson & JohnsonXarelto$311$18,02021 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,657 family providers in Michigan.

Other family in Vassar

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →